Catteau-Jonard S — Endo Lab

2026

GnRH-receptor antagonism as a targeted approach to reproductive dysfunction in polycystic ovary syndrome.

EBioMedicine ·doi:10.1016/j.ebiom.2026.106398

BackgroundPolycystic ovary syndrome (PCOS), recently renamed polyendocrine metabolic ovarian syndrome (PMOS), is characterised by neuroendocrine dysfunction with accelerated gonadotrophin-releasing hormone (GnRH)/luteinising hormone (LH) pu…

2025

Feasibility and efficacy of random-start progestin-primed ovarian stimulation: a multicenter pilot randomized controlled trial in oocyte donation.

Reproductive biology and endocrinology : RB&E ·doi:10.1186/s12958-025-01509-6

PURPOSE: We aimed to assess the impact of the timing of ovarian stimulation initiation on the number of oocytes retrieved in a progestin-primed ovarian stimulation (PPOS) protocol for oocyte donors. METHODS: A total of 110 oocyte donors wer…

2025

Prevalence and Recognition of Cardiovascular Risk Factors in 308 Women Consulting Their GP for Any Reason.

Women's health reports (New Rochelle, N.Y.) ·doi:10.1177/26884844251383337

IntroductionCardiovascular disease remains the leading cause of death among women. Across the lifespan, exposure to both traditional and lifestyle-related cardiovascular risk factors (CVRFs) is high. Behavioral trends such as increased sede…

2024

Genetic Landscape of a Cohort of 120 Patients with Diminished Ovarian Reserve: Correlation with Infertility.

International journal of molecular sciences ·doi:10.3390/ijms252211915

Diminished ovarian reserve (DOR) and primary ovarian insufficiency (POI) are major causes of female infertility. We recently found a monogenic etiology in 29.3% of POI, leading to personalized medicine. The genetic landscape of DOR is unkno…

2024

Is oral dydrogesterone equivalent to vaginal micronized progesterone for luteal phase support in women receiving oocyte donation?

Reproductive biology and endocrinology : RB&E ·doi:10.1186/s12958-024-01322-7

Research questionTo determine whether the use of oral dydrogesterone (DYD) in luteal phase support (LPS) during an artificial cycle provides equivalent clinical and ongoing pregnancy, delivery and miscarriage rates as micronized vaginal pro…

2023

How to Choose the Optimal Starting Dose of Clomiphene Citrate (50 or 100 mg per Day) for a First Cycle of Ovulation Induction in Anovulatory PCOS Women?

Journal of clinical medicine ·doi:10.3390/jcm12154943

Research questionClomiphene citrate (CC) is one of the first-line treatments for ovulation induction in women with anovulatory polycystic ovary syndrome (PCOS). However, nearly 1 out of 2 women is resistant to 50 mg/day of CC. The objective…

2016

Does polycystic ovarian morphology influence the response to treatment with pulsatile GnRH in functional hypothalamic amenorrhea?

Reproductive biology and endocrinology : RB&E ·doi:10.1186/s12958-016-0159-8

BackgroundPulsatile GnRH therapy is the gold standard treatment for ovulation induction in women having functional hypothalamic amenorrhea (FHA). The use of pulsatile GnRH therapy in FHA patients with polycystic ovarian morphology (PCOM), c…